<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332121</url>
  </required_header>
  <id_info>
    <org_study_id>B001-101</org_study_id>
    <nct_id>NCT03332121</nct_id>
  </id_info>
  <brief_title>B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma</brief_title>
  <official_title>Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection(B001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It's the first-in-human study of Recombinant Humanized Anti-CD20 Monoclonal Antibody for&#xD;
      Injection (B001). The main purpose of this study is to explore the safety and tolerance of&#xD;
      B001 for patients with CD20 positive B-cell non Hodgkin's lymphoma. It will also explore the&#xD;
      PK/PD manner and ORR in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I dose escalation study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2018</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of B001 as assessed by adverse reactions and events</measure>
    <time_frame>42 days</time_frame>
    <description>Incidence and intensity of adverse events according to NCI CTCAE 4.03 associated with increasing doses of B001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration-time curve of B001</measure>
    <time_frame>112 days</time_frame>
    <description>Measure the concentration of B001 in serum at different time point to get a concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD results of B001</measure>
    <time_frame>112 days</time_frame>
    <description>Measure the number of CD19 positive B cell in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of B001</measure>
    <time_frame>112 days</time_frame>
    <description>Content analysis of anti-B001 antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR of B001</measure>
    <time_frame>112 days</time_frame>
    <description>Objective response rate according to Response Criteria for Lymphoma（not including PET）and CLL Response Criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>CD20 Positive B Cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>B001,B001 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>B001</intervention_name>
    <description>4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77</description>
    <arm_group_label>B001,B001 dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of 18-75, male or female.&#xD;
&#xD;
          2. Patients with the following histologically-documented hematologic malignancy: CD20&#xD;
             positive B-cell non Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) or&#xD;
             small lymphocytic lymphoma (SLL), according to 2016 WHO Classification of Lymphoma.&#xD;
&#xD;
          3. Patients with relapsed/refractory CD20 positive B cell NHL (including CLL/SLL )&#xD;
&#xD;
          4. Life expectancy of at least 6 months.&#xD;
&#xD;
          5. ECOG-PS score of 0-1.&#xD;
&#xD;
          6. For patients of reproductive potential, pregnancy test should be negative 7 days&#xD;
             before treatment , and use of a reliable means of contraception during the study and&#xD;
             12months after discontinuing treatment. Males should be willing to use barrier&#xD;
             contraception during the study and 12months after discontinuing treatment.&#xD;
&#xD;
          7. Provision of signed and dated ,written informed consent prior to any study specific&#xD;
             procedures, sampling and analyses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious blood, renal or hepatic function impairment:&#xD;
&#xD;
               -  Absolute neutrophil count(ANC)&lt;1.0*10^9/L（Except for those with bone marrow&#xD;
                  invasion）&#xD;
&#xD;
               -  Lymphocyte Count(LYM)&gt;50*10^9/L&#xD;
&#xD;
               -  Haemoglobin(Hb)&lt;70g/L（Except for those with bone marrow invasion）&#xD;
&#xD;
               -  Platelet count(PLT)&lt;50*10^9/L（Except for those with bone marrow invasion）&#xD;
&#xD;
               -  Creatinine (Cr)&gt;1.5xULN&#xD;
&#xD;
               -  Alanine transaminase (ALT)or Aspartate aminotransferase(AST)&gt;2.5xULN&#xD;
&#xD;
               -  Total bilirubin (TBIL)&gt;2xULN&#xD;
&#xD;
          2. Patients with any anti-tumor treatment (including steroid treatment) within 4 weeks or&#xD;
             with any chronic unresolved toxicities from prior therapy greater than Grade 2&#xD;
             according to NCI-CTCAE 4.03.&#xD;
&#xD;
          3. Rituximab or any other anti-CD20 monoclonal antibody treatment within 3 weeks.&#xD;
&#xD;
          4. received blood transfusion and hemopoietic stimulating factor,eg. colony-stimulating&#xD;
             factor (CSF)、Erythropoietin(EPO) within 2 weeks.&#xD;
&#xD;
          5. Radiotherapy within 3 months.&#xD;
&#xD;
          6. Major surgery within 28 days&#xD;
&#xD;
          7. History of tumor vaccine treatment.&#xD;
&#xD;
          8. Live-virus (live attenuated) vaccine treatment within 28 days&#xD;
&#xD;
          9. High dose of steroid treatment (hydroprednisone &gt;10mg/day or relevant dose of other&#xD;
             drugs)&#xD;
&#xD;
         10. Patients with history of hematopoietic stem cell transplantation or planning to&#xD;
             receive hematopoietic stem cell transplantation within 3 months.&#xD;
&#xD;
         11. Patients with history of Gastrointestinal perforation and/or fistula within 6 months.&#xD;
&#xD;
         12. Lymphoma in CNS, ADIS related lymphoma&#xD;
&#xD;
         13. Active infection by bacteria,virus,fungus which required hospitalization or severe&#xD;
             infection required intravenous administration of antibiotics&#xD;
&#xD;
         14. Concomitant severe disease including but not limited to:&#xD;
&#xD;
               -  Known HIV or ADIS related disease&#xD;
&#xD;
               -  Asthma or interstitial lung disease or severe COPD&#xD;
&#xD;
               -  Myocardial infarction, unstable angina, Cardiovascular interventional surgery,&#xD;
                  Congestive heart failure(CHF; NYHA Grade II-IV), symptomatic or poorly controlled&#xD;
                  arrhythmia within 6 months before enrolling&#xD;
&#xD;
               -  The systolic pressure ≥140mmHg,or diastolic pressure≥90mmHg post treatment.&#xD;
&#xD;
               -  Acute or chronic hypotension(&lt;90/60mmHg)&#xD;
&#xD;
               -  History of toxic epidermal necrolysis or Stevens-Johnson syndrome&#xD;
&#xD;
               -  Rheumatoid arthritis Granulomatous angiitis or microscopic polyangiitis&#xD;
&#xD;
               -  Ileus or history of following disease: inflammatory bowel disease or extensive&#xD;
                  intestinal resection(extensive bowel resection or hemicolectomy, combining&#xD;
                  chronic diarrhea), Crohn's disease, ulcerative colitis or chronic diarrhea.&#xD;
&#xD;
               -  Previous or concomitant malignant, except basal-cell carcinoma or squamous cell&#xD;
                  carcinoma and/or cervical carcinoma in situ or effectively treated hematological&#xD;
                  malignancy and solid tumor that has been remission for more than 3 years and is&#xD;
                  considered to be cured.&#xD;
&#xD;
               -  Any history may affect the study result: increasing dosing risk or affect lab&#xD;
                  values and Judgment by the investigator that the patient should not participate&#xD;
                  in the study,&#xD;
&#xD;
         15. HBsAg positive; HBcAb positive and HBV-DNA≥upper limit of detection, HCV positive; HIV&#xD;
             positive&#xD;
&#xD;
         16. Allergy to humanized antibody or human-mouse chimeric antibody.&#xD;
&#xD;
         17. Woman who are breast feeding or pregnant&#xD;
&#xD;
         18. Judgment by the investigator that the patient should not participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lugui Qiu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junyuan Qi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The second affiliated hospital of Guangzhou medical university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

